BRENO DE ALENCAR ARARIPE FALCAO

(Fonte: Lattes)
Índice h a partir de 2011
5
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: MICHELI ZANOTTI GALON ×

Resultados de Busca

Agora exibindo 1 - 6 de 6
  • bookPart
    Manejo de introdutores arteriais e suas complicações
    (2015) GALON, Micheli Zanotti; CONEJO, Fábio; FALCãO, Breno de Alencar Araripe
  • bookPart
    Manejo de introdutores arteriais e suas complicações
    (2018) BEZERRA, Cristiano Guedes; GALON, Micheli Zanotti; CONEJO, Fábio; FALCãO, Breno de Alencar Araripe
  • article 3 Citação(ões) na Scopus
    Remoção Precoce do Introdutor Arterial Após Intervenção Coronária Percutânea por Via Femoral: Estudo de Segurança e Eficácia
    (2014) ZAGO, Gabriel; TRENTIN, Fabio; PRADO JR., Guy F. A.; SPADARO, Andre Gasparini; SILVA, Expedito Eustáquio Ribeiro da; CAMPOS, Carlos Magalhães; PERIN, Marco Antonio; FALCÃO, Breno de Alencar Araripe; ESTEVES-FILHO, Antonio; KAJITA, Luiz Junya; GAMA, Marcus Nogueira da; MARCHIORI, Gilberto; HORTA, Pedro Eduardo; TAKIMURA, Celso Kiyochi; MARIANI JR., Jose; GALON, Micheli Zanotti; SOARES, Paulo Rogerio; ZALC, Silvio; KALIL-FILHO, Roberto; LEMOS NETO, Pedro Alves
    Introduction: We evaluated the safety and efficacy of protamine administration, guided by activated clotting time, for the immediate femoral arterial sheath removal in patients undergoing percutaneous coronary intervention with unfractionated heparin in order to propose an algorithm for clinical practice. Methods: Prospective study with consecutive patients with stable angina or low-to-moderate risk acute coronary syndrome. We compared patients with an early removal of the arterial sheath to those whose sheath removal was based on a standard protocol. Results: The early removal group (n = 149) had lower access manipulation time than the conventional group (58.3 ± 21.4 minutes vs. 355.0 ± 62.9 minutes; p < 0.01), mainly due to a reduced time to sheath removal (42.3 ± 21.1 minutes vs. 338.6 ± 61.5 minutes; p < 0.01), with no impact on the duration of femoral compression (16.0 ± 3.6 minutes vs. 16.4 ± 5.1 minutes; p = 0.49). There was no stent thrombosis during hospitalization and no significant differences in the incidence of major vascular or bleeding events. The incidence of other bleeding events leading to a prolonged in-hospital length of stay was lower in the early removal group (1.3% vs. 5.1%; p = 0.05). Conclusions: The selective use of an approach for immediate femoral sheath removal, based on activated clotting time guidance and protamine administration, is a safe and effective option in patients undergoing percutaneous coronary intervention by femoral access.
  • bookPart
    Manejo de introdutores arteriais e suas complicações
    (2015) GALON, Micheli Zanotti; CONEJO, Fábio; FALCãO, Breno de Alencar Araripe
  • conferenceObject
    A New Thin-Strut, Low-Dose, Sirolimus-Eluting Stent With Abluminal-Only Biodegradable Polymeric Coating: Safety and Efficacy Clinical Performance of the Inspiron (TM) Stent in High-Risk Patients
    (2014) PRADO JR., Guy F. A.; MELO, Pedro Henrique Craveiro; TAKIMURA, Celso; ALVES, Gustavo M.; GUIMARAES, Welingson V.; MARIANI JR., Jose; KAJITA, Luiz J.; CAMPOS, Carlos M.; FALCAO, Breno A.; GAMA, Marcus N.; MARCHIORI, Gilberto; ESTEVES-FILHO, Antonio; HORTA, Pedro E.; GALON, Micheli Z.; SPADARO, Andre G.; ZALC, Silvio; SOARES, Paulo R.; PERIN, Marco A.; RIBEIRO, Expedito; KALIL-FILHO, Roberto; LEMOS, Pedro A.
  • article
    Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice
    (2015) PRADO JR., Guy F. A.; RIBEIRO, Expedito E.; MELO, Pedro H. M. C.; PINTON, Fabio A.; ESTEVES-FILHO, Antonio; TAKIMURA, Celso K.; MARIANI JR., Jose; KAJITA, Luiz J.; MARCHIORI, Gilberto; FALCAO, Breno de Alencar Araripe; GALON, Micheli Z.; SOARES, Paulo R.; ZALC, Silvio; LEMOS, Pedro A.
    Background: The present study aimed to evaluate the clinical performance, in the daily practice of a busy catheterization laboratory, of a novel drug-eluting stent (DES) built with an ultra-thin-strut metallic platform, eluting sirolimus at low doses, abluminal coated with biodegradable polymers, and mounted in a low-compliant delivery system. Methods: Prospective, single-arm study, comprising all consecutive patients undergoing percutaneous coronary intervention (PCI) with the Inspiron (TM) sirolimus-eluting stent (SES) (Scitech, Aparecida de Goiania, Brazil). The primary endpoint was the occurrence of major adverse cardiac events (MACE) [cardiac death, non-PCI related myocardial infarction (MI), or target vessel revascularization (TVR)]. Results: A total of 470 patients were included, from which 51.3% were diabetics, 33.8% had triple-vessel disease, 15.3% had heart failure, 38.9% had at least one bifurcation treated, 19.8% were treated for a bare metal stent restenosis, and 61.9% had at least one type C lesion; one or more of these features were found in 96.0%. At 300 days, the rate target lesion revascularization was 5.4% and the rate of MACE was 8.1%. The incidence of definite or probable stent thrombosis was 0.4%, with no cases between 30 and 300 days. Conclusions: The novel stent is associated with excellent short and mid-term clinical outcomes in patients treated with PCI in the daily practice.